FHA
RXRX icon

First Horizon Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

First Horizon Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$22.7K Sell
4,488
-2,405
-35% -$11.8K ﹤0.01% 1370
2025
Q1 		$36.5K Sell
6,893
-1,652
-19% -$12K ﹤0.01% 1073
2024
Q4 		$57.8K Buy
8,545
+487
+6% +$3.27K ﹤0.01% 889
2024
Q3 		$53.1K Buy
8,058
+1,157
+17% +$8.29K ﹤0.01% 960
2024
Q2 		$51.8K Buy
6,901
+707
+11% +$6.17K ﹤0.01% 902
2024
Q1 		$61.8K Buy
6,194
+1,429
+30% +$15.9K ﹤0.01% 855
2023
Q4 		$47K Buy
+4,765
New +$34K ﹤0.01% 968

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

First Horizon Advisors's RXRX Position: Q2 2025 in Review

First Horizon Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 35% in Q2 2025, selling an estimated $11.8K and leaving 4,488 shares worth $22.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1370.

First Horizon Advisors first reported a position in RXRX in Q4 2023 and has held it in 7 quarters since. The position peaked at $61.8K in Q1 2024. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • First Horizon Advisors held 4,488 shares of Recursion Pharmaceuticals worth $22.7K as of Q2 2025.
  • First Horizon Advisors sold 2,405 Recursion Pharmaceuticals shares in Q2 2025, an estimated $11.8K.
  • Recursion Pharmaceuticals made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1370 holding.
  • First Horizon Advisors first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
  • First Horizon Advisors's Recursion Pharmaceuticals position peaked at $61.8K in Q1 2024.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.